Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 17, 2026

JPMorgan Chase (JPM) Stock After 25% Yearly Gain Is The Price Still Reasonable

View original at finance.yahoo.com
JPMorgan Chase (JPM) Stock After 25% Yearly Gain Is The Price Still Reasonable Never miss an important update on your stock portfolio and cut through the noise…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • JPMorgan Chase scores just 2 out of 6 on Simply Wall St's valuation checks, with multiple red flags identified

    60% confidence

  • Analysts estimate a stable earnings figure of US$24.65 per share and a stable book value of US$145.37 per share for JPMorgan Chase, based on forward-looking ROE inputs from 12 analysts

    60% confidence

  • Over 7 million investors trust Simply Wall St for stock portfolio updates

    60% confidence

  • JPMorgan Chase stock is approximately 24.0% undervalued based on the Excess Returns valuation model, with an intrinsic value estimate of US$435.81 per share versus a market price of US$331.14

    60% confidence

  • The average Return on Equity used in the Excess Returns model is 16.96%, with a cost of equity of US$11.65 per share and an excess return of US$13.00 per share

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
JPMorgan Chase (JPM) Stock After 25% Yearly Gain Is The Price Still Reasonable — Source | Via News | ViaNews Market